Recs

7

The Action Never Stops at Dow Chemical

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

Dow Chemical (NYSE: DOW  ) continues to be in an extreme action state.

The company conducted its annual meeting late last week, after we had passed along information on a couple of major Dow financings, plus news of its participation in a new project in China. During the meeting, Dow shareholders decided to flex their muscles a little bit.

At a time when the fortunes of their own company appear to be brightening -- some would say amazingly -- shareholders of Dow Chemical, by an ultra-skinny 50.1% positive vote, have joined their peers at other big companies like Pfizer (NYSE: PFE  ) and Apple (Nasdaq: AAPL  ) in adopting a shareholder "say on pay" measure.

Similar "say on pay" measures have been turned down at companies like Johnson & Johnson (NYSE: JNJ  ) and Abbott Labs (NYSE: ABT  ) . And while the measure doesn't give stockholders real authority to set executives' compensation, it does allow them an annual opinion on the levels of pay being doled out. Even though CEO Andrew Liveris' 2008 pay had already been reduced by nearly two million dollars from 2007, he may be in line for more reductions in the future if shareholders aren’t happy with his continued performance.

But the owners of Dow didn't stop by invoking "say on pay." By a 58% vote, they also authorized a nonbinding proposal that would permit representatives of 10% of the shares to call special meetings to vote on significant matters affecting the company.

These shareholder measures notwithstanding, Dow is improving its lot at warp speed. After overloading his balance sheet to complete an acquisition of Rohm & Haas, the company has trimmed a portion of those excesses through debt and equity offerings and recently signed on with Royal Dutch Shell (NYSE: RDS-A  ) , to build a new refinery in Guangdong province, China.

Monday, in easily the most promising move of all, Dow announced that it'll raise its prices by three or four cents per pound on a couple of its key products. The products -- acrylic monomers and vinyl acetate -- are used in a host of goods, including clothes and glues. Pleased investors sent shares up 7% on what could be a possible sign that economic spring is arriving. Indeed, the CEO of chemical maker Celanese (NYSE: CE  ) said as much last week.

Given my strong feelings that shareholders deserve at least one hand on the till of most big companies these days, I'm actually in favor of the votes at Dow. Nevertheless, I think it's clear that Liveris and his crew have done a superb job of navigating their company through some rough waters. For that reason, I'd advise Fools to keep a close eye on Dow's future course.  

For related Foolishness:

The Steve Jobs Betrayal
You may already know that in the final year of his life, Jobs revealed a stunning betrayal — and told his biographer, "I will spend my last dying breath... and every penny of Apple's $40 billion in the bank to right this wrong." What was it that made Jobs so irate — and why could it make a few in-the-know investors some major profits over the coming months and years?

Enter your email address below to find out what made Jobs so enraged!

Fool contributor David Lee Smith doesn't own shares in any of the companies mentioned. He does, however, welcome your questions or comments. Apple is a Motley Fool Stock Advisor selection. Pfizer is a Motley Fool Inside Value recommendation. Johnson & Johnson is a Motley Fool Income Investor pick. Try any of our Foolish newsletters today, free for 30 days. The Motley Fool has a disclosure policy.


Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On May 19, 2009, at 4:29 PM, Buffhear wrote:

    As people follow Dow, it is interesting how Andrew Liveris will be made out to be some sort of hero or great savior for getting them out of the pickle that HE got them into. Remember, as you attempt to make him a hero, Dow's dividend was reduced by a factor of four because he bought one house (Rohm and Haas) before he sold the other one (the Kuwait deal). For what we criticize consumers who over leverage their ability to pay for their houses, we make it sound like a CEO did something marvelous by getting out of a an over leveraged mess he created.

  • Report this Comment On May 20, 2009, at 12:11 PM, strategic101 wrote:

    The choice of acquisition is opinion, the economic meltdown not Andrew's fault and the recent tactics of improving the balance sheet are professionally executed. However, there shall be no excuses for a CEO who signs a deal with no emergency exit for economic force-majeur. I fully concur with Buffhear - don't commend the instigator for his contributions in cleaning up this disaster, and, don't forget it almost brought down the entire company!

Add your comment.

Compare Brokers

Fool Disclosure

DocumentId: 902759, ~/Articles/ArticleHandler.aspx, 5/25/2012 8:16:01 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 12,454.83 -74.92 -0.60%
S&P 500 1,317.82 -2.86 -0.22%
NASD 2,837.53 -1.85 -0.07%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

5/25/2012 4:00 PM
DOW $31.30 Down -0.25 -0.79%
The Dow Chemical C… CAPS Rating: ****
JNJ $62.51 Down -0.59 -0.94%
Johnson & Johnson CAPS Rating: *****
PFE $22.13 Down -0.01 -0.05%
Pfizer, Inc. CAPS Rating: ****
RDS-A $62.83 Down -0.19 -0.30%
Royal Dutch Shell… CAPS Rating: ****
AAPL $562.29 Down -3.03 -0.54%
Apple CAPS Rating: ***
ABT $62.25 Down -0.17 -0.27%
Abbott Laboratorie… CAPS Rating: *****
CE $40.78 Down -0.03 -0.07%
Celanese Corp CAPS Rating: ***

Advertisement